Jianming Xu

机构：Guangxi University, ZHAW Zurich University of Applied Sciences, University of Zurich, Department of Biomedicine Basel · ORCID：0009-0007-5645-4158

发表论文 124 篇 · 总被引 1906 次 · h-index 18

代表论文

Long-term care system for older adults in China: policy landscape, challenges, and future prospects (2020 · The Lancet · 被引 667)
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial (2024 · Cancer Medicine · 被引 54)
Covalent PARylation of DNA base excision repair proteins regulates DNA demethylation (2024 · Nature Communications · 被引 29)
Inhibition of KIF20A by transcription factor IRF6 affects the progression of renal clear cell carcinoma (2021 · Cancer Cell International · 被引 22)
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. (2023 · Journal of Clinical Oncology · 被引 9)
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. (2022 · Journal of Clinical Oncology · 被引 8)